CM
RMD icon

Castleark Management’s ResMed RMD Stock Holding History

Castleark Management’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-30,705
Closed -$2.21M – 427
2017
Q1 		$2.21M Buy
+30,705
New +$2.12M 0.07% 262
2013
Q3 		– Sell
-1,525
Closed -$69K – 394
2013
Q2 		$69K Buy
+1,525
New +$72.4K ﹤0.01% 308

Other funds holding RMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Castleark Management's RMD Position: Q2 2017 in Review

Castleark Management sold out of ResMed (RMD) in Q2 2017, closing a stake of 30,705 shares — an estimated $2.21M sold.

Castleark Management first reported a position in RMD in Q2 2013 and held it in 2 quarters. The position peaked at $2.21M in Q1 2017. 339 funds tracked by Wall St. Rank hold RMD as of Q2 2017.

  • Castleark Management reported no remaining ResMed position as of Q2 2017 after selling out during the quarter.
  • Castleark Management sold 30,705 ResMed shares in Q2 2017, an estimated $2.21M.
  • Castleark Management first reported a position in ResMed in Q2 2013 and held it in 2 quarters.
  • Castleark Management's ResMed position peaked at $2.21M in Q1 2017.
  • 339 funds tracked by Wall St. Rank held ResMed as of Q2 2017.

Based on Castleark Management's 13F filing for Q2 2017, filed 15 Aug 2017.